About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Disease Progression in ms | Clinical Trials | Clareo Health

Back to clinical trial search

Not Yet RecruitingNCT07292116

Disease Progression in ms

Demographic and clinical data will be obtained from people with MS. Based on this data, the progression of the disease will be predicted with artificial intelligence.

Lead sponsor: Hüseyin Bektaş•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Hüseyin Bektaş

Demographic and clinical data will be obtained from people with MS. Demographic data; age, gender, disease type, disease duration. Clinical data; Frailty, Physical Activity Level, Walking, Balance, Fatigue, Quality of Life. Based on these data, disease progression will be predicted with artificial intelligence and motor learning.

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Having been diagnosed with MS

Exclusion Criteria

•be literate

Related studies

Development of Pain Management JITAI Content in Multiple Sclerosis and Spinal Cord Injury

NCT07663266 · Multiple Sclerosis, Spinal Cord Injury

RECRUITINGPhase 3

A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis

NCT07189325 · Relapsing-Remitting Multiple Sclerosis (RRMS), Anti-CD20 Therapy

RECRUITINGPhase 2

Solriamfetol for the Treatment of Multiple Sclerosis Fatigue

NCT06170970 · Multiple Sclerosis, Multiple Sclerosis Fatigue

RECRUITINGPhase 2

A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity

NCT06782490 · Multiple Sclerosis Spasticity

RECRUITINGPhase 3

A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis

NCT07299019 · Secondary Progressive Multiple Sclerosis

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: December 18, 2025Terms

Trial snapshot

StatusNOT_YET_RECRUITING

Phase—

Enrollment53

Start dateDec 2025

Last updatedDec 18, 2025

Condition

Prediction of Disease Progression Multiple Sclerosis

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 18, 2025Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions